stockrowAdaptive Biotechnologies Corporation
ADPT Healthcare Diagnostics & Research
Adaptive Biotechnologies Corporation’s revenue for fiscal 2025 (year ended December 2025) was $277.0 million, up 54.8% from fiscal 2024.
- Revenue
- −10.7%
- EPS
- −66.7%
- Free cash flow
- +201.9%
Quarter to September 2026, against a year earlier
Follow ADPT
Alert me
Adaptive Biotechnologies Corporation (ADPT) Shares outstanding
Adaptive Biotechnologies Corporation's shares outstanding at the end of fiscal 2025 was $151.7M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $186.9M. Over the past ten years it has ranged from $12.2M (fiscal 2017) to $151.7M (fiscal 2025) — the current reading is the highest in ten years. Adaptive Biotechnologies Corporation ranks 8th of 49 Diagnostics & Research companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $151.7M | 3.14% |
| FY2024 | $147.1M | 1.88% |
| FY2023 | $144.4M | 1.31% |
| FY2022 | $142.5M | 1.54% |
| FY2021 | $140.4M | 6.96% |
| FY2020 | $131.2M | 89.71% |
| FY2019 | $69.2M | 447.63% |
| FY2018 | $12.6M | 3.55% |
| FY2017 | $12.2M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $186.9M | 16.91% |
| Jun 2026 | $159.9M | 2.79% |
| Mar 2026 | $155.5M | 2.50% |
| Dec 2025 | $151.7M | (7.01%) |
| 29 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| SHC Sotera Health Company compare | $289.2M |
| ADPT Adaptive Biotechnologies Corporation | $186.9M |
| NEO NeoGenomics, Inc. compare | $128.6M |
| VCYT Veracyte, Inc. compare | $82.8M |
| RDNT RadNet, Inc. compare | $78.7M |
| CDNA CareDx, Inc. compare | $55.0M |
| BLLN BillionToOne, Inc. compare | $53.7M |
| GRAL GRAIL, Inc. compare | $46.8M |
| WGS GeneDx Holdings Corp. compare | $29.7M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on ADPT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement